SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
Rhea-AI Summary
SI-BONE (Nasdaq: SIBN) reported preliminary, unaudited fourth quarter and full year 2025 results. For Q4 2025 the company expects worldwide revenue of $56.2–$56.3 million (~15% growth) and U.S. revenue of $53.3–$53.4 million (~14% growth). Q4 active U.S. physicians rose to ~1,640 (up 250, ~18%). Cash and cash equivalents were ~$147.7 million, implying net cash generation of ~$2.0 million in the quarter. For fiscal 2025 the company expects worldwide revenue of $200.8–$200.9 million (~20% growth) and U.S. revenue of $190.9–$191.0 million (~21% growth). These figures are preliminary and subject to adjustment pending financial close and audit; final results will be provided on the Q4 2025 earnings call in late February 2026.
Positive
- Worldwide revenue +~20% for FY2025 to $200.8–$200.9M
- U.S. revenue +~21% for FY2025 to $190.9–$191.0M
- Q4 2025 worldwide revenue +~15% to $56.2–$56.3M
- Active U.S. physicians +~18% to ~1,640 (Q4 2025)
- Ending cash and equivalents of ~ $147.7M
Negative
- Results are preliminary and unaudited, subject to adjustment after close and audit
- Quarterly net cash generation was modest at ~ $2.0M for Q4 2025
News Market Reaction
On the day this news was published, SIBN declined 12.57%, reflecting a significant negative market reaction. Argus tracked a trough of -9.0% from its starting point during tracking. Our momentum scanner triggered 46 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $128M from the company's valuation, bringing the market cap to $887M at that time. Trading volume was elevated at 2.9x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SIBN fell 2.11% while peers showed mixed moves: TNDM -5.78%, OFIX -1.5%, AXGN +0.9%, AVNS +0.57%, ZIMV 0%. This points to stock-specific trading rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 18 | Conference appearance | Neutral | +1.3% | Piper Sandler healthcare conference presentation and webcast details. |
| Nov 10 | Earnings beat/guidance | Positive | -0.6% | Strong Q3 growth, margin improvement, positive EBITDA and raised 2025 guidance. |
| Nov 10 | Earnings update | Positive | -0.6% | Second-quarter 2025 results with strong revenue growth and updated guidance. |
| Oct 20 | Earnings date notice | Neutral | +2.0% | Announcement of timing and call details for Q3 2025 results. |
| Aug 26 | Conference appearance | Neutral | +1.0% | Participation in Morgan Stanley Global Healthcare Conference with webcast access. |
Recent earnings reports with positive fundamentals have sometimes seen modest negative price reactions, while conference and scheduling announcements have tended to coincide with small gains.
Over the past six months, SI-BONE has reported multiple periods of strong revenue growth and improving profitability. In Q3 2025, revenue and margins improved and guidance was raised, yet the stock slipped slightly. Earlier 2025 results also showed double-digit growth and positive adjusted EBITDA. Conference appearances in August and November 2025, plus earnings date announcements in October 2025, coincided with small positive moves. Today’s preliminary 2025 revenue and cash update extends that growth narrative into the fourth quarter and full year.
Market Pulse Summary
The stock dropped -12.6% in the session following this news. A negative reaction despite solid preliminary numbers would fit a pattern where strong earnings updates have not always translated into gains. Fiscal 2025 revenue of $200.8–$200.9M and Q4 revenue above $56M suggest continued double‑digit growth, yet past quarters with similar strength saw mild declines. Investors may weigh risks such as revisions when audits conclude or concerns about sustainability of growth, even as cash and equivalents of about $147.7M provide balance‑sheet support.
AI-generated analysis. Not financial advice.
Fiscal Year 2025 worldwide revenue of
SANTA CLARA, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year 2025.
Fourth Quarter 2025 Summary (any comparisons are to the prior year period)
- Worldwide revenue between
$56.2 -$56.3 million , representing ~15% growth - U.S. revenue between
$53.3 -$53.4 million , representing ~14% growth - ~1,640 active physicians in the U.S., an increase of 250 physicians, representing ~
18% growth - Cash and equivalents of ~
$147.7 million , implying net cash generation of ~$2.0 million in the quarter
Fiscal Year 2025 Summary (any comparisons are to the prior year period)
- Worldwide revenue between
$200.8 -$200.9 million , representing ~20% growth - U.S. revenue between
$190.9 -$191.0 million , representing ~21% growth
The fourth quarter and full year 2025 revenue and cash and equivalents are included in this release on a preliminary basis, prior to the completion of SI-BONE's financial closing procedures and audit procedures by its external auditors and therefore may be subject to adjustment. SI-BONE expects to provide fourth quarter and full year 2025 financial results during its fourth quarter 2025 earnings call in late February 2026.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is the global leader in developing procedural solutions to address clinical challenges associated with compromised bone. SI-BONE's expertise in additive manufacturing has resulted in a technology platform with market-leading applications in SI joint fusion, adult spinal deformity and pelvic trauma. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including four randomized controlled trials and over 200 peer reviewed publications.
For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.
SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved.
Forward Looking Statements
The statements in this press release regarding expectations of future events or results, including SI-BONE’s expectations of continued revenue and procedure growth and financial outlook, are “forward-looking” statements. These forward-looking statements are based on SI-BONE’s current expectations and inherently involve significant risks and uncertainties. These risks include SI-BONE's preliminary fourth quarter and full year 2025 revenue and cash and cash equivalents, which are subject to continued review by SI-BONE and its auditors and significant adjustments may be made before final results are determined, SI-BONE’s ability to introduce and commercialize new products and indications, SI-BONE’s ability to maintain favorable reimbursement for procedures using its products, the impact of any future economic weakness or deterioration in economic conditions as a result of tariffs and retaliation by U.S. trading partners on the ability and desire of patients to undergo elective procedures including those using SI-BONE’s products, SI-BONE’s ability to manage risks to its supply chain, future capital requirements driven by new surgical systems requiring instrument tray and implant inventory investment, and the pace of the re-normalization of the healthcare operating environment including the ability and desire of patients and physicians to undergo and perform procedures using SI-BONE’s products. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these and other risks and uncertainties, many of which are described in SI-BONE’s most recent filings on Form 10-K and Form 10-Q, and SI-BONE’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov), especially under the caption “Risk Factors.” SI-BONE does not undertake any obligation to update forward-looking statements and expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.
Investor Contact
Saqib Iqbal
VP, FP&A, and Investor Relations
investors@SI-BONE.com
FAQ
What preliminary revenue did SI-BONE (SIBN) report for fiscal 2025?
What were SI-BONE's preliminary Q4 2025 revenue and U.S. revenue (SIBN)?
How many active U.S. physicians did SI-BONE report in Q4 2025 (SIBN)?
What cash position did SI-BONE (SIBN) report at the end of Q4 2025?
Are SI-BONE's Q4 and FY2025 numbers final for SIBN shareholders?
When will SI-BONE (SIBN) release audited Q4 and FY2025 results?
